SCHEMBL2074517

SCHEMBL2074517

OC[C@H](O)CCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.52
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP12 P39900 1/20 0.50
MMP13 P45452 1/20 0.50
MMP14 P50281 1/20 0.50
DPP4 P27487 1/20 0.50
ANPEP P15144 2/20 0.46
ERAP1 Q9NZ08 2/20 0.46
ERAP2 Q6P179 1/20 0.46
ACP3 P15309 1/20 0.44
TSHR P16473 1/20 0.44
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
KCNH2 Q12809 1/20 0.43
CNR2 P34972 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2074824 1.00 TDP1 (0.52) TDP1MMP2MMP9MMP12MMP13
SCHEMBL2077325 1.00 TDP1 (0.52) TDP1MMP2MMP9MMP12MMP13
SCHEMBL4799370 0.88 MMP2 (0.55) TDP1MMP2MMP9MMP12MMP13
SCHEMBL11452418 0.88 MMP12 (0.67) MMP2MMP9MMP12MMP13MMP14
SCHEMBL11549188 0.87 TRPA1 (0.51) TDP1SLC6A3
SCHEMBL101260 0.85 TRPA1 (0.58) TDP1SLC6A3
SCHEMBL18863862 0.84 TDP1 (0.56) TDP1MMP2MMP9MMP12MMP13
SCHEMBL27370822 0.84 TRPA1 (0.61) TDP1
SCHEMBL27177813 0.84 TRPA1 (0.61) TDP1
SCHEMBL448011 0.82 TRPA1 (0.56) TDP1MMP2MMP9MMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0317998-B1 Manufacturing method of optically-active 1,2-diols KANEGAFUCHI CHEMICAL IND (JP) 1994-08-31 EP claimed
CN-114106329-B Phospholipid double-layer membrane for nanopore gene sequencing and preparation method thereof 四川大学 2022-08-09 CN disclosed
CN-114106329-A Phospholipid double-layer membrane for nanopore gene sequencing and preparation method thereof 四川大学 2022-03-01 CN disclosed
US-20150031898-A1 PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES INSTYTUT FARMACEUTYCZNY (PL) 2015-01-29 US disclosed
US-7897793-B2 Forming latanoprost; alkylation; reductive desulfurization INSTYTUT FARMACEUTYCZNY (PL) 2011-03-01 US disclosed
US-20090093651-A1 PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES INSTYTUT FARMACEUTYCZNY (PL) 2009-04-09 US disclosed
US-20080207926-A1 PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES INSTYTUT FARMACEUTYCZNY (PL) 2008-08-28 US disclosed
EP-1891005-A2 PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES INSTYTUT FARMACEUTYCZNY (PL) 2008-02-27 EP disclosed
WO-2006112742-A2 PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES INSTYTUT FARMACEUTYCZNY (PL) 2006-10-26 WO disclosed
EP-1098885-B9 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO (JP) 2005-05-18 EP disclosed
EP-1098885-B1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO (JP) 2004-11-17 EP disclosed
US-6359145-B1 ADENOSINE DEAMINASE INHIBITOR; ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANT FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-19 US disclosed
EP-1098885-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-16 EP disclosed
WO-2001026605-A2 IMMUNOSUPPRESSIVE COMPOSITION CONTAINING IL-2 INHIBITOR AND AN ADENOSINE DEAMINASE INHIBITOR FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-04-19 WO disclosed
WO-2000005217-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093651-A1 PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES PTGIS, PTGS2, PTGES2 TDP1 3839/4885MMP2 1520/4885MMP9 1579/4885
US-20080207926-A1 PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2 ALPHA DERIVATIVES PTGIS, PTGS2, PTGES2 TDP1 3839/4885MMP2 1520/4885MMP9 1579/4885
US-20150031898-A1 PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES PTGES, PTGIS, PTGES2 TDP1 3223/4885MMP2 4103/4885MMP9 3999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.